<?xml version="1.0" encoding="UTF-8"?>
<paload id="" version="">
	<toplevel>
		<routedMedId>156265</routedMedId>
		<routedMedName>Xarelto 20 mg tablet</routedMedName>
		<routedGenericName>rivaroxaban 20 mg tablet</routedGenericName>
		<etcIds>
			<etc_id/>
		</etcIds>
		<medIds>
			<medId>568102</medId>
		</medIds>
	</toplevel>
	<diagnoses>
		<diagnosis>
			<fqn>Pulmonary Thromboembolism without Valvular Heart Disorder</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>not specified</gender>
			<icd9>22.1475</icd9>
			<symbolic>PulmThromEmb</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name></name>
			</genotype>
			<polymorphism>
				<name></name>
			</polymorphism>
			<subtype>
				<name></name>
			</subtype>
			<severity>
				<name></name>
				<code></code>
				<dur></dur>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Not Applicable</name>
					<code>Not Applicable</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype></subtype>
					<inclusion_exclusion>exclusion</inclusion_exclusion>
					<dur></dur>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment> </treatment>
					</patientHxType>
					<preferredTherapy>
						<treatment> </treatment>
					</preferredTherapy>
				</criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.4096|02.77321|02.3949</codeValues>
								<selectedListName>warfarin oral</selectedListName>
								<selectedListClassCode>18.3949</selectedListClassCode>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Pradaxa oral</name>
								<codeValues>02.154839</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Presence of prosthetic heart valve</name>
								<codeValues>12.Z95.2</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<dosing>
				<text>15 mg orally 2 times per day for 21 days</text>
				<text>20 mg orally every day</text>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId>568102</medId>
					<initPerDayDesc>1 tablet</initPerDayDesc>
					<initPerIntervalDesc>1 tablet per day</initPerIntervalDesc>
					<renewPerDayDesc>1 tablet</renewPerDayDesc>
					<renewPerIntervalDesc>1 tablet per day</renewPerIntervalDesc>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur>12</dur>
					<durUnit>m</durUnit>
				</initialDur>
				<renewalDur>
					<dur>12</dur>
					<durUnit>m</durUnit>
				</renewalDur>
				<overallMax>
					<dur>12</dur>
					<durUnit>m</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Product Information: Xarelto. Janssen Pharmaceuticals, Inc., 2014.</reference>
				<reference>FDB/AHFS On-Line Pharmacy Reference.  Retrieved June 4, 2014, from http://inweb2/FDBReference/</reference>
				<reference>Guyatt GH, Akl EA, Crowther M, et al.  Executive Summary : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.  CHEST, 141(Suppl), 7S-47S.</reference>
				<reference>Patel MR, Mahaffey KW, Garg J, et al.  Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation.  N Engl J Med, 365, 883-91.</reference>
				<reference>The EINSTEIN-PE Investigators.  Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism.  N Engl J Med, 366, 1287-97.</reference>
				<reference>The EINSTEIN-PE Investigators.  Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism.  N Engl J Med, 363, 2499-510.</reference>
				<reference>Prins MH, Lensing AW, Bauersachs R, et al.  Oral Rivaroxaban versus Standard Therapy for the Treatment of Symptomatic venous Thromboembolism: A Pooled Analysis of the EINSTEIN-DVT and PE Randomized Studies.  Thromobsis Journal, 11, 21.</reference>
				<reference>Kwong LM.  Therapeutic Potential of Rivaroxaban in the Prevention of Venous Thromboembolism Following Hip and Knee Replacement Surgery: A Review of Clinical Trial Data.  Clinical Pharmacology: Advances and Applications, 2011:7, 461-46.</reference>
				<reference>Kwong LM.  Comparative Safety and Efficacy of Antithrombotics in the Management of Venous Thromboembolism After Knee or Hip Replacement Surgery: Focus on Rivaroxaban.  Clinical Pharmacology: Advances and Applications, 2013:5, 143-48.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
		</diagnosis>
		<diagnosis>
			<fqn>Pulmonary Thromboembolism Prevention without Valvular Heart Disorder</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>not specified</gender>
			<icd9>22.1477</icd9>
			<symbolic>PulmThromEmbPreven</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name></name>
			</genotype>
			<polymorphism>
				<name></name>
			</polymorphism>
			<subtype>
				<name></name>
			</subtype>
			<severity>
				<name></name>
				<code></code>
				<dur></dur>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Not Applicable</name>
					<code>Not Applicable</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype></subtype>
					<inclusion_exclusion>exclusion</inclusion_exclusion>
					<dur></dur>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment> </treatment>
					</patientHxType>
					<preferredTherapy>
						<treatment> </treatment>
					</preferredTherapy>
				</criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.4096|02.77321|02.3949</codeValues>
								<selectedListName>warfarin oral</selectedListName>
								<selectedListClassCode>18.3949</selectedListClassCode>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Pradaxa oral</name>
								<codeValues>02.154839</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
			</triedTherapyExclusion>
			<dosing>
				<text>20 mg orally every day</text>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId>568102</medId>
					<initPerDayDesc>1 tablet</initPerDayDesc>
					<initPerIntervalDesc>1 tablet per day</initPerIntervalDesc>
					<renewPerDayDesc>1 tablet</renewPerDayDesc>
					<renewPerIntervalDesc>1 tablet per day</renewPerIntervalDesc>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur>12</dur>
					<durUnit>m</durUnit>
				</initialDur>
				<renewalDur>
					<dur>12</dur>
					<durUnit>m</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Product Information: Xarelto. Janssen Pharmaceuticals, Inc., 2014.</reference>
				<reference>FDB/AHFS On-Line Pharmacy Reference.  Retrieved June 4, 2014, from http://inweb2/FDBReference/</reference>
				<reference>Guyatt GH, Akl EA, Crowther M, et al.  Executive Summary : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.  CHEST, 141(Suppl), 7S-47S.</reference>
				<reference>Patel MR, Mahaffey KW, Garg J, et al.  Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation.  N Engl J Med, 365, 883-91.</reference>
				<reference>The EINSTEIN-PE Investigators.  Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism.  N Engl J Med, 366, 1287-97.</reference>
				<reference>The EINSTEIN-PE Investigators.  Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism.  N Engl J Med, 363, 2499-510.</reference>
				<reference>Prins MH, Lensing AW, Bauersachs R, et al.  Oral Rivaroxaban versus Standard Therapy for the Treatment of Symptomatic venous Thromboembolism: A Pooled Analysis of the EINSTEIN-DVT and PE Randomized Studies.  Thromobsis Journal, 11, 21.</reference>
				<reference>Kwong LM.  Therapeutic Potential of Rivaroxaban in the Prevention of Venous Thromboembolism Following Hip and Knee Replacement Surgery: A Review of Clinical Trial Data.  Clinical Pharmacology: Advances and Applications, 2011:7, 461-46.</reference>
				<reference>Kwong LM.  Comparative Safety and Efficacy of Antithrombotics in the Management of Venous Thromboembolism After Knee or Hip Replacement Surgery: Focus on Rivaroxaban.  Clinical Pharmacology: Advances and Applications, 2013:5, 143-48.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
		</diagnosis>
		<diagnosis>
			<fqn>Deep Venous Thrombosis without Valvular Heart Disorder</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>not specified</gender>
			<icd9>22.1686</icd9>
			<symbolic>DVT</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name></name>
			</genotype>
			<polymorphism>
				<name></name>
			</polymorphism>
			<subtype>
				<name></name>
			</subtype>
			<severity>
				<name></name>
				<code></code>
				<dur></dur>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Not Applicable</name>
					<code>Not Applicable</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype></subtype>
					<inclusion_exclusion>exclusion</inclusion_exclusion>
					<dur></dur>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment> </treatment>
					</patientHxType>
					<preferredTherapy>
						<treatment> </treatment>
					</preferredTherapy>
				</criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.4096|02.77321|02.3949</codeValues>
								<selectedListName>warfarin oral</selectedListName>
								<selectedListClassCode>18.3949</selectedListClassCode>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Pradaxa oral</name>
								<codeValues>02.154839</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
			</triedTherapyExclusion>
			<dosing>
				<text>15 mg orally 2 times per day for 21 days</text>
				<text>20 mg orally every day</text>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId>568102</medId>
					<initPerDayDesc>1 tablet</initPerDayDesc>
					<initPerIntervalDesc>1 tablet per day</initPerIntervalDesc>
					<renewPerDayDesc>1 tablet</renewPerDayDesc>
					<renewPerIntervalDesc>1 tablet per day</renewPerIntervalDesc>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur>12</dur>
					<durUnit>m</durUnit>
				</initialDur>
				<renewalDur>
					<dur>12</dur>
					<durUnit>m</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Product Information: Xarelto. Janssen Pharmaceuticals, Inc., 2014.</reference>
				<reference>FDB/AHFS On-Line Pharmacy Reference.  Retrieved June 4, 2014, from http://inweb2/FDBReference/</reference>
				<reference>Guyatt GH, Akl EA, Crowther M, et al.  Executive Summary : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.  CHEST, 141(Suppl), 7S-47S.</reference>
				<reference>Patel MR, Mahaffey KW, Garg J, et al.  Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation.  N Engl J Med, 365, 883-91.</reference>
				<reference>The EINSTEIN-PE Investigators.  Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism.  N Engl J Med, 366, 1287-97.</reference>
				<reference>The EINSTEIN-PE Investigators.  Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism.  N Engl J Med, 363, 2499-510.</reference>
				<reference>Prins MH, Lensing AW, Bauersachs R, et al.  Oral Rivaroxaban versus Standard Therapy for the Treatment of Symptomatic venous Thromboembolism: A Pooled Analysis of the EINSTEIN-DVT and PE Randomized Studies.  Thromobsis Journal, 11, 21.</reference>
				<reference>Kwong LM.  Therapeutic Potential of Rivaroxaban in the Prevention of Venous Thromboembolism Following Hip and Knee Replacement Surgery: A Review of Clinical Trial Data.  Clinical Pharmacology: Advances and Applications, 2011:7, 461-46.</reference>
				<reference>Kwong LM.  Comparative Safety and Efficacy of Antithrombotics in the Management of Venous Thromboembolism After Knee or Hip Replacement Surgery: Focus on Rivaroxaban.  Clinical Pharmacology: Advances and Applications, 2013:5, 143-48.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
		</diagnosis>
		<diagnosis>
			<fqn>Deep Venous Thrombosis Prevention without Valvular Heart Disorder</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>not specified</gender>
			<icd9>22.1688</icd9>
			<symbolic>DVTPreven</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name></name>
			</genotype>
			<polymorphism>
				<name></name>
			</polymorphism>
			<subtype>
				<name></name>
			</subtype>
			<severity>
				<name></name>
				<code></code>
				<dur></dur>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Not Applicable</name>
					<code>Not Applicable</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype></subtype>
					<inclusion_exclusion>exclusion</inclusion_exclusion>
					<dur></dur>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment> </treatment>
					</patientHxType>
					<preferredTherapy>
						<treatment> </treatment>
					</preferredTherapy>
				</criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.4096|02.77321|02.3949</codeValues>
								<selectedListName>warfarin oral</selectedListName>
								<selectedListClassCode>18.3949</selectedListClassCode>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Pradaxa oral</name>
								<codeValues>02.154839</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
			</triedTherapyExclusion>
			<dosing>
				<text>20 mg orally every day</text>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId>568102</medId>
					<initPerDayDesc>1 tablet</initPerDayDesc>
					<initPerIntervalDesc>1 tablet per day</initPerIntervalDesc>
					<renewPerDayDesc>1 tablet</renewPerDayDesc>
					<renewPerIntervalDesc>1 tablet per day</renewPerIntervalDesc>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur>12</dur>
					<durUnit>m</durUnit>
				</initialDur>
				<renewalDur>
					<dur>12</dur>
					<durUnit>m</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Product Information: Xarelto. Janssen Pharmaceuticals, Inc., 2014.</reference>
				<reference>FDB/AHFS On-Line Pharmacy Reference.  Retrieved June 4, 2014, from http://inweb2/FDBReference/</reference>
				<reference>Guyatt GH, Akl EA, Crowther M, et al.  Executive Summary : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.  CHEST, 141(Suppl), 7S-47S.</reference>
				<reference>Patel MR, Mahaffey KW, Garg J, et al.  Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation.  N Engl J Med, 365, 883-91.</reference>
				<reference>The EINSTEIN-PE Investigators.  Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism.  N Engl J Med, 366, 1287-97.</reference>
				<reference>The EINSTEIN-PE Investigators.  Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism.  N Engl J Med, 363, 2499-510.</reference>
				<reference>Prins MH, Lensing AW, Bauersachs R, et al.  Oral Rivaroxaban versus Standard Therapy for the Treatment of Symptomatic venous Thromboembolism: A Pooled Analysis of the EINSTEIN-DVT and PE Randomized Studies.  Thromobsis Journal, 11, 21.</reference>
				<reference>Kwong LM.  Therapeutic Potential of Rivaroxaban in the Prevention of Venous Thromboembolism Following Hip and Knee Replacement Surgery: A Review of Clinical Trial Data.  Clinical Pharmacology: Advances and Applications, 2011:7, 461-46.</reference>
				<reference>Kwong LM.  Comparative Safety and Efficacy of Antithrombotics in the Management of Venous Thromboembolism After Knee or Hip Replacement Surgery: Focus on Rivaroxaban.  Clinical Pharmacology: Advances and Applications, 2013:5, 143-48.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
		</diagnosis>
		<diagnosis>
			<fqn>Prevention of Thromboembolism with Chronic Atrial Fibrillation without Valvular Heart Disorder</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>not specified</gender>
			<icd9>22.5673</icd9>
			<symbolic>PrevenThromEmbolwithChAFib</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name></name>
			</genotype>
			<polymorphism>
				<name></name>
			</polymorphism>
			<subtype>
				<name></name>
			</subtype>
			<severity>
				<name></name>
				<code></code>
				<dur></dur>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Not Applicable</name>
					<code>Not Applicable</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype></subtype>
					<inclusion_exclusion>exclusion</inclusion_exclusion>
					<dur></dur>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment> </treatment>
					</patientHxType>
					<preferredTherapy>
						<treatment> </treatment>
					</preferredTherapy>
				</criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.4096|02.77321|02.3949</codeValues>
								<selectedListName>warfarin oral</selectedListName>
								<selectedListClassCode>18.3949</selectedListClassCode>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Pradaxa oral</name>
								<codeValues>02.154839</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Eliquis oral</name>
								<codeValues>02.163073</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
			</triedTherapyExclusion>
			<dosing>
				<text>CrCl >50 mL/min: 20 mg once daily</text>
				<text>CrCl 15 to 50 mL/min: 15 mg once daily</text>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId>568102</medId>
					<initPerDayDesc>1 tablet</initPerDayDesc>
					<initPerIntervalDesc>1 tablet per day</initPerIntervalDesc>
					<renewPerDayDesc>1 tablet</renewPerDayDesc>
					<renewPerIntervalDesc>1 tablet per day</renewPerIntervalDesc>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur>12</dur>
					<durUnit>m</durUnit>
				</initialDur>
				<renewalDur>
					<dur>12</dur>
					<durUnit>m</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Product Information: Xarelto. Janssen Pharmaceuticals, Inc., 2014.</reference>
				<reference>FDB/AHFS On-Line Pharmacy Reference.  Retrieved June 4, 2014, from http://inweb2/FDBReference/</reference>
				<reference>Guyatt GH, Akl EA, Crowther M, et al.  Executive Summary : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.  CHEST, 141(Suppl), 7S-47S.</reference>
				<reference>Patel MR, Mahaffey KW, Garg J, et al.  Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation.  N Engl J Med, 365, 883-91.</reference>
				<reference>The EINSTEIN-PE Investigators.  Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism.  N Engl J Med, 366, 1287-97.</reference>
				<reference>The EINSTEIN-PE Investigators.  Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism.  N Engl J Med, 363, 2499-510.</reference>
				<reference>Prins MH, Lensing AW, Bauersachs R, et al.  Oral Rivaroxaban versus Standard Therapy for the Treatment of Symptomatic venous Thromboembolism: A Pooled Analysis of the EINSTEIN-DVT and PE Randomized Studies.  Thromobsis Journal, 11, 21.</reference>
				<reference>Kwong LM.  Therapeutic Potential of Rivaroxaban in the Prevention of Venous Thromboembolism Following Hip and Knee Replacement Surgery: A Review of Clinical Trial Data.  Clinical Pharmacology: Advances and Applications, 2011:7, 461-46.</reference>
				<reference>Kwong LM.  Comparative Safety and Efficacy of Antithrombotics in the Management of Venous Thromboembolism After Knee or Hip Replacement Surgery: Focus on Rivaroxaban.  Clinical Pharmacology: Advances and Applications, 2013:5, 143-48.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
		</diagnosis>
	</diagnoses>
	<precautions>
		<geriatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</geriatric>
		<pregnancy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pregnancy>
		<pediatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pediatric>
		<lactation>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</lactation>
		<allergy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</allergy>
		<sideEffect>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</sideEffect>
		<drugDisease>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</drugDisease>
	</precautions>
	<lists>
		<listDef>
			<name>warfarin oral</name>
			<codeValue>18.3949</codeValue>
			<listType>generic</listType>
			<listItem>
				<name>Coumadin oral</name>
				<codeValue>02.4096</codeValue>
			</listItem>
			<listItem>
				<name>Jantoven oral</name>
				<codeValue>02.77321</codeValue>
			</listItem>
			<listItem>
				<name>warfarin oral</name>
				<codeValue>02.3949</codeValue>
			</listItem>
		</listDef>
	</lists>
</paload>
